Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk
Status:
Completed
Trial end date:
2020-01-08
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to compare how two different drugs, decitabine
and azacitidine, when given on a shorter than standard dosing schedule can help to control
MDS. The safety of the drugs will also be studied.
Decitabine is designed to damage the DNA (the genetic material) of cells, which may cause
cancer cells to die.
Azacitidine is designed to block certain proteins in cancer cells whose job is to stop the
function of the tumor-fighting proteins. By blocking the "bad" proteins, the tumor-fighting
genes may be able to work better. This could cause the cancer cells to die.